Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Sustol (granisetron) Prior Auth | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0283

    Sustol (granisetron extended-release) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0283 alerts

    Get alerted when Policy IC-0283 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers prior authorization, dosing, clinical criteria, and billing for Sustol (granisetron extended-release) when used for prevention of chemotherapy-induced nausea and vomiting (CINV) in Viva Health members.

    Policy Summary
    PayerViva Health
    PolicySustol (granisetron extended-release) — Coverage Criteria
    Policy CodePolicy IC-0283
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial 180 days, not renewable) confirming member is ≥18, has documented failure of palonosetron, and meets regimen-specific combination therapy requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J1627HCPCS code
    180 daysInitial prior authorization duration
    Not renewableRenewal policy
    100Max HCPCS units / 7 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10 mg SC
    Dosage
    1-2Appendices included

    Coverage criteria

    Initial Approval for Prevention of CINV

    Covered when ALL of the following are met

    Age: Member must be at least 18 years of age>=18 years
    Clinical failure of palonosetron: Member has failed with palonosetron while receiving the current anticancer chemotherapy regimenfailure = two or more documented episodes of vomiting attributed to the current chemotherapy regimen
    Concomitant steroid: Sustol used in combination with dexamethasone

    Emetogenic regimen and additional antiemetics

    • HEC regimen option: Member is receiving highly emetogenic anticancer chemotherapy (HEC) AND Sustol is used with aprepitant (PO or IV), fosaprepitant, or rolapitant (with or without olanzapine)
    • MEC or AC regimen option: Member is receiving moderately emetogenic anticancer chemotherapy (MEC) OR an anthracycline plus cyclophosphamide (AC) regimen
    • 4-drug regimen option: Sustol used in combination with olanzapine, an NK-1 receptor antagonist, and dexamethasone as part of a 4-drug regimen when that 4-drug regimen has not been previously given
    Prior emesis or risk factors: One of the following is present: member experienced emesis during a previous cycle of anticancer chemotherapy with a 3-drug regimen (olanzapine- or NK-1 RA-containing), OR member has additional risk factors for anticancer agent–induced nausea/vomiting

    Risk factors are enumerated in policy

    Not for excluded uses: Requested use is not for breakthrough emesis and not for repeat dosing in multi-day emetogenic chemotherapy regimens more frequently than once every 7 days

    Sustol is NOT covered for these uses

    Sustol is not covered for management of breakthrough emesis. The policy explicitly excludes use of Sustol for breakthrough vomiting episodes that occur despite a scheduled antiemetic regimen.

    Sustol is also not covered for repeat dosing in multi-day emetogenic chemotherapy regimens (more frequently than once every 7 days). Doses given more often than once every 7 days in the setting of multi-day chemotherapy are outside the coverage criteria and should not be authorized.

    For Medicare Part B considerations the policy notes that the section is intended for non‑Medicare coverage determinations and directs users to CMS guidance. The document lists Medicare Part B Covered Diagnosis Codes: N/A for the non‑Medicare coverage determinations in this policy, and instructs reviewers to consult NCDs/LCDs/LCAs via the CMS coverage database where applicable.

    Initial therapy dosing and administration

    Initial Dosing

    Dosing and administration for initial therapy

    Dose and frequency: 10 mg administered subcutaneously by a healthcare provider on Day 1 of chemotherapy; not more frequently than once every 7 days10 mg per dose; once every >=7 days

    Corresponds to HCPCS J1627 where 1 unit = 0.1 mg

    Renewal and continuation criteria

    Renewal Criteria

    Renewal rules

    Renewal not allowed: Duration of the initial prior authorization has not been exceeded and prior authorization validity may NOT be renewedinitial 180 days

    Refer to section I for length of authorization

    Coding and billing

    HCPCS codeHCPCSCovered
    J1627Injection, granisetron, extended-release, 0.1 mg; 1 billable unit = 0.1 mg
    NDCNDCCovered
    47426-0101-xxSustol Extended-Release Injection 10 mg/0.4 mL single-dose pre-filled syringe: 47426-0101-xx
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    R11.0Nausea
    R11.10Vomiting, unspecified
    R11.11Vomiting without nausea
    R11.12Projectile vomiting
    R11.2Nausea with vomiting, unspecified
    T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
    T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
    T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
    T45.95XAAdverse effect of unspecified primarily systemic and hematological agent, initial encounter
    T45.95XDAdverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
    1–10 of 16
    1/2
    Covered ICD-10 CodesICD-10Covered
    R11.0Nausea
    R11.10Vomiting, unspecified
    R11.11Vomiting without nausea
    R11.12Projectile vomiting
    R11.2Nausea with vomiting, unspecified
    T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
    T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
    T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
    T45.95XAAdverse effect of unspecified primarily systemic and hematological agent, initial encounter
    T45.95XDAdverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
    1–10 of 16
    1/2
    Max HCPCS units per 7 days
    Maximum allowed100 billable units per 7 days (HCPCS unit; 1 unit = 0.1 mg)
    Unit definitionHCPCS unit corresponds to 0.1 mg granisetron (per J1627)
    TimeframeLimit applies over a rolling 7‑day period

    Provider actions, prior authorization, and documentation

    Prior Authorization

    Prior authorization required; initial 180 days, not renewable

    Prior authorization is required for Sustol. Initial authorization is valid for 6 months (180 days) and may NOT be renewed. Member must be at least 18 years of age and meet the policy’s clinical criteria for prevention of CINV, including prior palonosetron failure and required regimen-specific combination therapy.

    • Initial PA duration: 6 months (180 days).
    • Renewals: Not allowed (prior authorization may NOT be renewed).
    • Age requirement: Member must be ≥18 years.
    Note

    PA may be applied per NQTL considerations (indication, cost)

    The policy’s NQTL checklist identifies 'Indication' and 'Cost of drug' as factors considered when applying prior authorization; providers should be aware that PA may be applied for these reasons.

    • NQTL factors recorded: Indication = Yes (Consider for PA); Cost of drug = Yes (Consider for PA).

    Definitions and terms

    Failure (to palonosetron)
    Failure definitionTwo or more documented episodes of vomiting attributed to the current chemotherapy regimen
    Context for useRequired documentation of palonosetron failure while receiving the current anticancer chemotherapy regimen
    PurposeUsed to establish need for alternative antiemetic (Sustol) per policy step requirement
    HEC / MEC
    HEC (Highly emetogenic chemotherapy)Regimens/agents enumerated in policy appendices considered HEC (examples include cisplatin; carboplatin AUC ≥4; cyclophosphamide >1500 mg/m2; select high‑dose or combination regimens such as FOLFIRINOX, FOLFIRI, AC); see policy appendix for full list
    MEC (Moderately emetogenic chemotherapy)Agents/regimens listed as MEC in the policy appendix (examples include select cytotoxic and targeted agents shown in Appendix; see policy text for full enumeration)

    Step therapy requirements

    StepRequirementFailure definitionCoverage status
    1Trial and documented failure of palonosetron while receiving the current anticancer chemotherapy regimen is required prior to approvalFailure defined as two or more documented episodes of vomiting attributed to the current chemotherapy regimenCovered with criteria
    StepPolicy considerationNQTL factors citedCoverage status
    1Prior authorization may be considered based on indication and drug cost per the NQTL assessment; used to inform application of PA for this drugIndication: Yes — consider for PA; Cost of drug: Yes — consider for PA; Safety/efficacy and misuse/abuse: NoNeutral (policy consideration for PA)

    Quantity limits and site of care

    granisetron extended-release (Sustol) — Quantity limit
    Packaged quantity (policy)100 billable units per 7 days stated as the quantity limit for granisetron extended‑release (Sustol)
    HCPCS code noteCorresponds to J1627 where 1 billable unit = 0.1 mg (use HCPCS billing to apply the 100‑unit limit)
    Dosage relationPolicy dosing is 10 mg subcutaneously on Day 1 (equates to 100 units), not more frequently than once every 7 days

    Site of care

    Billing Rule

    Site‑of‑care: must be administered subcutaneously by a provider (office)

    Sustol is administered subcutaneously by a healthcare provider and must be given in an office or other provider‑administered setting per the dosing instructions.

    • Dose: 10 mg SC on Day 1 of chemotherapy; not more frequently than once every 7 days
    • Administration: by a healthcare provider (office setting)

    Background

    Sustol (granisetron extended‑release) is an extended‑release formulation of the 5‑HT3 receptor antagonist granisetron, provided as a subcutaneous injection for prevention of chemotherapy‑induced nausea and vomiting (CINV). It is intended for administration by a healthcare provider as part of multi‑drug antiemetic regimens tailored to the emetogenic risk of the patient’s chemotherapy and is used when the policy’s clinical criteria (including prior palonosetron failure and regimen‑specific combination therapy requirements) are met.

    Policy Summary
    PayerViva Health
    PolicySustol (granisetron extended-release) — Coverage Criteria
    Policy CodePolicy IC-0283
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial 180 days, not renewable) confirming member is ≥18, has documented failure of palonosetron, and meets regimen-specific combination therapy requirements.
    SourceLink
    On This Page
    Coverage criteriaInitial therapy dosing and administrationRenewal and continuation criteriaCoding and billingProvider actions, prior authorization, and documentationDefinitions and termsStep therapy requirementsQuantity limits and site of careSite of careBackground
    Step Therapy

    Must trial and fail palonosetron on current regimen before approval

    Approval requires a documented trial and failure of palonosetron while the member is receiving the current anticancer chemotherapy regimen before Sustol will be approved for CINV prevention.

    • Step requirement: Trial and documented failure of palonosetron while on the current anticancer regimen is required prior to approval.
    Step Therapy

    No other explicit step therapy requirements stated

    No additional or alternate step therapy requirements are specified in the policy beyond the palonosetron failure requirement.

    Documentation Required

    Document palonosetron failure (two or more vomiting episodes)

    Provide documentation showing failure with palonosetron as defined by the policy: two or more documented episodes of vomiting attributed to the current chemotherapy regimen while receiving the current anticancer regimen.

    • Failure definition: two or more documented episodes of vomiting attributed to the current chemotherapy regimen.
    • Documentation must tie episodes of vomiting to the current anticancer chemotherapy regimen.
    Note

    Reference Sustol package insert and NCCN Compendium

    Refer to the Sustol (granisetron extended-release) package insert and the NCCN Drugs & Biologics Compendium (Antiemesis) for clinical support and cited references when submitting PA requests.

    • Reference: Sustol package insert (Heron Therapeutics, Feb 2026).
    • Reference: NCCN Drugs & Biologics Compendium — Antiemesis (Version 1.2026).
    Documentation Required

    Use listed ICD-10 codes (Appendix 1) to support indication

    Support the clinical indication with one of the covered ICD-10 diagnosis codes listed in Appendix 1 (for example R11.0, R11.10, R11.11, R11.12, R11.2, T45.1X5A, Z51.11, Z51.12).

    • Use an Appendix 1 ICD-10 code from the policy’s Covered Diagnosis Codes to support the PA request.
    Denial Risk

    Do not request coverage for breakthrough emesis or repeat multi-day dosing

    Sustol is not covered for breakthrough emesis or for repeat dosing in multi-day emetogenic chemotherapy regimens (i.e., more frequently than once every 7 days); do not request coverage for these situations.

    • Exclusions: Breakthrough emesis.
    • Exclusions: Repeat dosing in multi-day regimens more frequently than once every 7 days.
    Denial Risk

    PA may be denied for members <18 or for renewal/duration requests

    PA may be denied if the member is under 18 years of age or if a renewal is requested (renewals are not allowed) or the initial authorization duration has been exceeded.

    • Age risk: Member <18 years — PA may be denied.
    • Renewal/duration risk: Renewals are not permitted; authorization may be denied if duration exceeded.
    Prior Authorization

    PA consideration may be based on indication and cost (NQTL)

    Per the NQTL checklist, prior authorization may be considered based on the clinical indication and the cost of the drug; include indication-specific justification and any cost-related documentation if relevant to the request.

    • NQTL considerations that led to PA: Indication = Consider for PA; Cost of drug = Consider for PA.
    Regimen notesUse of Sustol is tied to regimen emetogenicity and must be combined with dexamethasone and specified NK‑1 RA or olanzapine as detailed in the coverage criteria
    NQTL
    DefinitionNon‑quantitative treatment limitations (NQTLs) are methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan
    ExamplesMay include utilization review or prior authorization and other management techniques
    ApplicationNQTL checklist factors (e.g., indication, cost of drug) were considered when designing prior authorization for this drug